keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg Clearance

keyword
https://www.readbyqxmd.com/read/29149205/kir-content-genotypes-associate-with-carriage-of-hepatitis-b-surface-antigen-e-antigen-and-hbv-viral-load-in-gambians
#1
Louis-Marie Yindom, Maimuna Mendy, Christopher Bodimeade, Caroline Chambion, Peter Aka, Hilton C Whittle, Sarah L Rowland-Jones, Robert Walton
BACKGROUND: Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in low income countries, and incidence is rising rapidly in the developed world with the spread of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infections and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in determining both outcome of initial hepatitis infection and subsequent chronic liver disease and tumour formation...
2017: PloS One
https://www.readbyqxmd.com/read/29131246/study-on-the-distribution-of-cd8-memory-t-cell-subsets-and-ifn-%C3%AE-level-during-the-spontaneous-clearance-of-hepatitis-b-virus-in-patients-with-chronic-hepatitis-b-virus-infection
#2
X-J Ma, X-F Chen, W-L Chen, R Chen, J Huang, X-D Luo, J-Y Liao, X-P Chen
OBJECTIVE: To study the alteration of CD8+ memory T cell subsets under different immune statuses during the spontaneous clearance of hepatitis B virus (HBV) in Chinese patients with chronic HBV infection. PATIENTS AND METHODS: We analyzed Chinese patients with chronic HBV infection including 10 patients with Hepatitis B surface Antigen (HBsAg) spontaneous seroconversion, 25 patients with Hepatitis B virus e Antigen (HBeAg) spontaneous seroconversion, 25 patients with chronic hepatitis B (CHB), and 25 chronic HBV carriers...
October 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29108132/incidence-and-predictors-of-hbsag-seroclearance-after-cessation-of-nucleos-t-ide-analogue-therapy-in-hbeag-negative-chronic-hepatitis-b
#3
Wen-Juei Jeng, Yi-Cheng Chen, Rong-Nan Chien, I-Shyan Sheen, Yun-Fan Liaw
Hepatitis B s antigen (HBsAg) loss is a rare event during nucleos(t)ide analogue (Nuc) therapy. Limited data suggest that stopping Nuc therapy may increase HBsAg loss rate in hepatitis B e antigen (HBeAg) negative patients. A large study was conducted to investigate this issue in more detail. Of the 1075 HBeAg-negative patients treated with Nuc for 156 (61-430) weeks, 6 showed HBsAg seroclearance during treatment at an estimated annual incidence of 0.15%. Of the patients who remained HBsAg seropositive, 691 (52...
November 6, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29082651/comparison-of-208-week-sequential-therapy-with-telbivudine-and-entecavir-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-responses-to-24%C3%A2-weeks-of-peg-ifn%C3%AE-2a-therapy-an-open-labelled-randomized-controlled-real-life-trial
#4
X D Luo, X F Chen, Y Zhou, X P Chen
The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. This was an open-label, randomized, controlled, "real-life" trial. HBeAg-positive CHB patients with serum HBV DNA ≥5.0 lg IU/mL and a < 1 lg IU/mL decline of HBsAg level from baseline who underwent at least 24 weeks of Peg-IFNα-2a therapy were included. Enrolled patients were randomized to receive either telbivudine (600 mg/d, n = 95) or entecavir (0...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29062901/new-directions-in-hepatitis-b-therapy-research
#5
REVIEW
Marta Lewandowska, Anna Piekarska
Chronic hepatitis B treatment is available for a long period, allowing disease control and infection suppression, but it is rarely responsible for HBsAg clearance. None of the drugs available aim at cccDNA, the obstacle in HBV infection eradication. Complications related to CHB, such as liver insufficiency, cirrhosis, and hepatocellular carcinoma are reduced in conditions of good viremia suppression, but still exist even after HBsAg seroclearance, what makes a need for urgent forthcoming of new therapeutics...
September 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/29056007/-clinical-effect-of-156-week-telbivudine-sequential-therapy-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-response-to-pegylated-interferon-%C3%AE-2a-therapy
#6
X D Luo, X P Chen, X F Chen
Objective: To investigate the clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a (Peg-IFN-α-2a) therapy. Methods: A total of 35 HBeAg-positive CHB patients with HBV DNA < 500 IU/ml who were treated with Peg-IFN-α-2a for 48 weeks and did not experience seroconversion of HBeAg were given telbivudine sequential therapy for 156 weeks. HBeAg clearance rate, HBeAg seroconversion rate, HBV DNA clearance rate, safety, and drug resistance rate were analyzed...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29052304/immunotherapy-for-hepatitis-b-in-the-direct-acting-anti-viral-era-reevaluating-the-thymosin-%C3%AE-1-efficacy-trials-in-light-of-a-combination-therapy-approach
#7
Paul H Naylor, Milton G Mutchnick
Hepatitis B virus (HBV) causes both acute and chronic hepatitis and infects large numbers of individuals worldwide. Unfortunately, prediction of typical clinical outcome is problematic and there is considerable variability in the frequency, duration and severity of disease progression. The mainstay of HBV treatment is directed towards the suppression of HBV replication by nucleos(t)ide analogs (NUCs). The use of immunomodulators such as α-Interferon and thymosin α1 can, in select patients, result in elimination of both HBsAg and HBeAg...
October 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29032635/prevalence-and-natural-course-of-occult-hepatitis-b-virus-infection-in-residents-of-two-communities-of-wuwei-city-gansu-province-china
#8
Xiaohui Wen, Haixia Su, Yang Wang, Zhongshu Pu, Jie Gao, Zhaohua Ji, Xiaojie Yuan, Xiaochun Li, Weilu Zhang, Lei Zhang, Yong Long, Yongping Yan, Zhongjun Shao
Occult hepatitis B infection (OBI) is characterized by serum hepatitis B surface antigen (HBsAg) negative and hepatitis B virus (HBV) DNA positive (HBsAg-/HBV DNA+). OBI in community-based populations has been scarcely investigated, and OBI outcomes remain unclear, especially in Wuwei, a region located in Northwest China. This region is one of the areas in China that has the highest prevalence of chronic HBV infection. A prospective study was performed in the general population of two towns of Wuwei from June 2011 to May 2014...
October 15, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28940887/association-of-human-leukocyte-antigen-polymorphisms-with-occult-hepatitis-b-virus-infection-in-a-shaanxi-han-population
#9
Tianju Wang, Chunmei Shen, Liping Chen, Sheng Liu, Yanhong Ji
BACKGROUND: Occult hepatitis B virus (HBV) infection (OBI) is defined as HBV DNA detection in serum or in the liver by sensitive diagnostic tests in HBV surface antigen (HBsAg) negative patients with or without serologic markers of previous HBV exposure. Because the human leukocyte antigen (HLA) system is an integral component of the immune response, we hypothesized that the highly polymorphic HLA genes were the key determinants of HBV persistence and clearance. The present study aimed to calculate the allelic frequency of HLA loci and investigate the association between HLA alleles and the outcome of OBI in Shaanxi Han population in the northwest of China...
September 2017: Journal of Gene Medicine
https://www.readbyqxmd.com/read/28903779/hepatitis-delta-virological-and-clinical-aspects
#10
REVIEW
Luan Felipo Botelho-Souza, Mariana Pinheiro Alves Vasconcelos, Alcione de Oliveira Dos Santos, Juan Miguel Villalobos Salcedo, Deusilene Souza Vieira
There are an estimated 400 million chronic carriers of HBV worldwide; between 15 and 20 million have serological evidence of exposure to HDV. Traditionally, regions with high rates of endemicity are central and northern Africa, the Amazon Basin, eastern Europe and the Mediterranean, the Middle East and parts of Asia. There are two types of HDV/HBV infection which are differentiated by the previous status infection by HBV for the individual. Individuals with acute HBV infection contaminated by HDV is an HDV/HBV co-infection, while individuals with chronic HBV infection contaminated by HDV represent an HDV/HBV super-infection...
September 13, 2017: Virology Journal
https://www.readbyqxmd.com/read/28875955/efficacy-of-real-world-entecavir-therapy-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#11
Yan-Di Xie, Hui Ma, Bo Feng, Lai Wei
Background: Entecavir (ETV) has been shown to be effective in randomized controlled trials in highly selected patients with hepatitis B virus (HBV) infection. This study aimed to evaluate the efficacy of ETV in chronic hepatitis B (CHB) patients in the real-world setting. Methods: A total of 233 treatment-naïve, CHB patients who received at least 12 months of ETV treatment were included in this retrospective study. Rates of virological response (VR), hepatitis B s antigen (HBsAg) loss, hepatitis B e antigen (HBeAg) clearance/seroconversion, virological breakthrough, cirrhosis, and hepatocellular carcinoma were evaluated...
September 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28869890/development-of-anti-hepatitis-b-surface-hbs-antibodies-after-hbs-antigen-loss-in-hiv-hepatitis-b-virus-co-infected-patients
#12
Anders Boyd, Laetitia Canini, Joël Gozlan, Caroline Lascoux-Combe, Patrick Miailhes, Laurent Fonquernie, Pierre-Marie Girard, Karine Lacombe
BACKGROUND: Hepatitis B surface antigen (HBsAg)-seroconversion, or loss of HBsAg and acquisition of anti-hepatitis B surface (HBs) antibodies, defines functional cure of chronic hepatitis B virus (HBV) infection. After HBsAg-loss, little is known regarding the development of anti-HBs antibodies and even less so in individuals co-infected with HIV. OBJECTIVES: To determine anti-HBs antibody kinetics after HBsAg-loss and explore determinants of HBsAg-seroconversion in HIV-HBV co-infected patients...
August 25, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28856289/recommendations-for-the-treatment-of-hepatitis-b-in-2017
#13
REVIEW
Robert Flisiak, Waldemar Halota, Jerzy Jaroszewicz, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Anna Piekarska, Krzysztof Simon, Krzysztof Tomasiewicz, Marta Wawrzynowicz-Syczewska
The therapeutic goal which is currently unfrequent but realistic in HBV infected patients is sustained HBsAg clearance. It is preceded by the loss or significant suppression of HBV replication and leads to inhibition of the progression of liver fibrosis, normalization of biochemical indicators of liver damage, reduction in the risk of hepatocellular carcinoma, prolongation of survival, prevention of HBV infection in the transplanted organ in post-transplant patients, enhancement of the quality of life, inhibition or reversal of extrahepatic changes associated with HBV infection, and halting of the spread of HBV infections...
June 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/28822954/the-variability-of-hepatitis-b-envelope-is-associated-with-hbs-antigen-persistence-in-either-chronic-or-acute-hbv-genotype-a-infection
#14
Marine Eschlimann, Brice Malvé, Aurélie Velay, Honorine Fenaux, Sibel Berger, Jean-Pol Frippiat, Fabien Zoulim, Mouni Bensenane, Jean-Pierre Bronowicki, François Goehringer, Thierry May, Hélène Jeulin, Evelyne Schvoerer
BACKGROUND: More than 240 million people are chronically infected by hepatitis B virus (HBV) worldwide. Envelope proteins play a crucial role in viral cellular entry and immune recognition. The loss of HBs antigen (HBsAg) correlated with a good clinical prognosis is rarely achieved with or without treatment (3-16%). OBJECTIVES: HBV envelope variability was investigated according to HBsAg persistence. STUDY DESIGN: The cohort consisted of 15 HBV genotype A-infected patients divided into "resolvers", with HBsAg clearance, and "non-resolvers", with HBsAg persistence and in subgroups: acute (n=5, AHBV) or chronic infection (n=4, CHBV) and HBV/HIV coinfection (n=6, CHBV/HIV)...
August 5, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28802168/impact-of-hepatitis-b-vaccination-on-hbsag-kinetics-interferon-inducible-protein-10-level-and-recurrence-of-viremia
#15
Amr Shaaban Hanafy
BACKGROUND AND AIMS: Persistent HBs antigenemia >1000IU/ml has a possibility of viral reactivation and HCC in 8%, so we investigated the effect of HBV vaccine on HBsAg, IP-10, and recurrence of viremia. METHODS: Group I: inactive carriers(n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 1year after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or3years after DNA disappearance in HBeAg negativepatients (n=60). All showed persistent HBs antigenemia...
August 9, 2017: Cytokine
https://www.readbyqxmd.com/read/28792701/predictive-value-of-hepatitis-b-core-related-antigen-hbcrag-during-the-natural-history-of-hepatitis-b-virus-infection
#16
Yu Gou, Yanhua Zhao, Chenli Rao, Shu Feng, Tingting Wang, Dongdong Li, Chuanmin Tao
BACKGROUND: The natural history of HBV infection includes immune tolerance (IT), immune clearance (IC), HBeAg-negative inactive/quiescent carrier (ENQ), and HBeAg-negative hepatitis (ENH) phases. As the current biomarkers for discriminating the four phases still have some weaknesses, additional serological indicators are needed. Hepatitis B core-related antigen (HBcrAg) encoded with the precore/core gene contains denatured HBeAg, HBV core antigen (HBcAg), and a 22-KDa precore protein (p22cr) and has been demonstrated to have a close association with the natural history of hepatitis B infection...
July 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28750917/predictive-role-of-serum-hbsag-and-hbcrag-kinetics-in-patients-with-hbeag-negative-chronic-hepatitis-b-receiving-pegylated-interferon-based-therapy
#17
N Chuaypen, N Posuwan, S Chittmittraprap, N Hirankarn, S Treeprasertsuk, Y Tanaka, N Shinkai, Y Poovorawan, P Tangkijvanich
OBJECTIVES: To investigate the role of serum hepatitis B core-related antigen (HBcrAg) kinetics in predicting long-term outcome of pegylated interferon (PEG-IFN)-based therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). METHODS: A total of 121 Thai patients with HBeAg-negative CHB recruited from a previous randomized trial of 48-week PEG-IFN alone or combined with entecavir were enrolled. Hepatitis B surface antigen (HBsAg) and HBcrAg levels were serially examined...
July 24, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28738454/-development-of-markov-models-for-economics-evaluation-of-strategies-on-hepatitis-b-vaccination-and-population-based-antiviral-treatment-in-china
#18
P C Yang, S X Zhang, P P Sun, Y L Cai, Y Lin, Y H Zou
Objective: To construct the Markov models to reflect the reality of prevention and treatment interventions against hepatitis B virus (HBV) infection, simulate the natural history of HBV infection in different age groups and provide evidence for the economics evaluations of hepatitis B vaccination and population-based antiviral treatment in China. Methods: According to the theory and techniques of Markov chain, the Markov models of Chinese HBV epidemic were developed based on the national data and related literature both at home and abroad, including the settings of Markov model states, allowable transitions and initial and transition probabilities...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28732143/ifnl4-rs368234815-and-rs117648444-variants-predict-off-treatment-hbsag-seroclearance-in-ifn-treated-hbeag-negative-chronic-hepatitis-b-patients
#19
Enrico Galmozzi, Floriana Facchetti, Glenda Grossi, Alessandro Loglio, Mauro Viganò, Giovanna Lunghi, Massimo Colombo, Pietro Lampertico
BACKGROUND & AIM: Robust baseline predictors of interferon (IFN) response in HBeAg-negative chronic hepatitis B (CHB) patients are not currently available. The recently described rs368234815 TT/ΔG dinucleotide and rs117648444 nonsynonymous P70S polymorphisms in IFN lambda 4 (IFNL4) gene, which are strongly associated with response to IFN in hepatitis C virus (HCV) infection, could be also useful in IFN-treated CHB patients. Here we assessed whether IFNL4 rs368234815 and rs117648444 polymorphisms predict IFN-induced HBsAg clearance in CHB patients...
July 21, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28699816/enrichment-of-ly6c-hi-monocytes-by-multiple-gm-csf-injections-with-hbv-vaccine-contributes-to-viral-clearance-in-a-hbv-mouse-model
#20
Weidong Zhao, Xian Zhou, Gan Zhao, Qing Lin, Xianzheng Wang, Xueping Yu, Bin Wang
Adjuvants are considered a necessary component for HBV therapeutic vaccines but few are licensed in clinical practice due to concerns about safety or efficiency. In our recent study, we established that a combination protocol of 3-day pretreatments with GM-CSF before a vaccination (3 × GM-CSF+VACCINE) into the same injection site could break immune tolerance and cause over 90% reduction of HBsAg level in the HBsAg transgenic mouse model. Herein, we further investigated the therapeutic potential of the combination in AAV8-1...
July 12, 2017: Human Vaccines & Immunotherapeutics
keyword
keyword
42773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"